As a result, these findings suggested an enhanced NRF2 activity and functional inactivation of KEAP1 in order to discriminate a molecular signature of specific subtype of NSCLC, defined by resistance to treatment and accelerated disease progression [78]. Here, NFE2L2 is linked to non-small cell lung carcinoma.